These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20883031)

  • 21. Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors.
    Dolado I; Nieto J; Saraiva MJ; Arsequell G; Valencia G; Planas A
    J Comb Chem; 2005; 7(2):246-52. PubMed ID: 15762752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S; Rossello A; Orlandini E
    ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors.
    Zanotti G; Cendron L; Folli C; Florio P; Imbimbo BP; Berni R
    FEBS Lett; 2013 Aug; 587(15):2325-31. PubMed ID: 23792159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aboard transthyretin: From transport to cleavage.
    Liz MA; Mar FM; Franquinho F; Sousa MM
    IUBMB Life; 2010 Jun; 62(6):429-35. PubMed ID: 20503435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. X-ray crystallographic studies of two transthyretin variants: further insights into amyloidogenesis.
    Neto-Silva RM; Macedo-Ribeiro S; Pereira PJ; Coll M; Saraiva MJ; Damas AM
    Acta Crystallogr D Biol Crystallogr; 2005 Mar; 61(Pt 3):333-9. PubMed ID: 15735344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TTR fibril formation inhibitors: is there a SAR?
    Nencetti S; Orlandini E
    Curr Med Chem; 2012; 19(15):2356-79. PubMed ID: 22471984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity.
    Ferreira N; Cardoso I; Domingues MR; Vitorino R; Bastos M; Bai G; Saraiva MJ; Almeida MR
    FEBS Lett; 2009 Nov; 583(22):3569-76. PubMed ID: 19861125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational design of potent human transthyretin amyloid disease inhibitors.
    Klabunde T; Petrassi HM; Oza VB; Raman P; Kelly JW; Sacchettini JC
    Nat Struct Biol; 2000 Apr; 7(4):312-21. PubMed ID: 10742177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural stabilization of transthyretin by a new compound, 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione.
    Yokoyama T; Takaki S; Chosa K; Sato T; Suico MA; Teranishi Y; Shuto T; Mizuguchi M; Kai H
    J Pharmacol Sci; 2015 Dec; 129(4):240-3. PubMed ID: 26639444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
    Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of 4H-1,4-oxazines as transthyretin amyloid fibril inhibitors.
    Li W; Duan X; Yan H; Xin H
    Org Biomol Chem; 2013 Jul; 11(27):4546-50. PubMed ID: 23733168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
    Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
    Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential use of glucuronylglucosyl-β-cyclodextrin as a novel therapeutic tool for familial amyloidotic polyneuropathy.
    Jono H; Anno T; Motoyama K; Misumi Y; Tasaki M; Oshima T; Mori Y; Mizuguchi M; Ueda M; Shinriki S; Shono M; Obayashi K; Arima H; Ando Y
    Amyloid; 2012 Jun; 19 Suppl 1():50-2. PubMed ID: 22620966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
    Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
    Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cys114-linked dimers of transthyretin are compatible with amyloid formation.
    Karlsson A; Olofsson A; Eneqvist T; Sauer-Eriksson AE
    Biochemistry; 2005 Oct; 44(39):13063-70. PubMed ID: 16185074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding and stabilization of transthyretin by curcumin.
    Pullakhandam R; Srinivas PN; Nair MK; Reddy GB
    Arch Biochem Biophys; 2009 May; 485(2):115-9. PubMed ID: 19268650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular dynamics studies of the process of amyloid aggregation of peptide fragments of transthyretin.
    Paci E; Gsponer J; Salvatella X; Vendruscolo M
    J Mol Biol; 2004 Jul; 340(3):555-69. PubMed ID: 15210354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased thermodynamic stability as a crucial factor for familial amyloidotic polyneuropathy.
    Niraula TN; Haraoka K; Ando Y; Li H; Yamada H; Akasaka K
    J Mol Biol; 2002 Jul; 320(2):333-42. PubMed ID: 12079390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conserved water mediated H-bonding dynamics of Ser117 and Thr119 residues in human transthyretin-thyroxin complexation: inhibitor modeling study through docking and molecular dynamics simulation.
    Banerjee A; Bairagya HR; Mukhopadhyay BP; Nandi TK; Mishra DK
    J Mol Graph Model; 2013 Jul; 44():70-80. PubMed ID: 23732306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The binding of synthetic triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative and non-cooperative ligand recognition.
    Trivella DB; Sairre MI; Foguel D; Lima LM; Polikarpov I
    J Struct Biol; 2011 Feb; 173(2):323-32. PubMed ID: 20937391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.